FOLH1 and Familial prostate cancer: Unlike the current FDA-approved PSMA PET tracers, low levels of kidney uptakes were noted with 89Zr-DFO-MSTP2109A, and 16 of the 17 PET-positive lesions were biopsy proven to be prostate cancer.